Bioxytran Inc (BIXT) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BIXT Annual Balance Sheets →
Looking at balance sheet data from Bioxytran Inc through Jun 30 2025 provides insight into Jun 30 2026's solvency and capital structure over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent0.18
Cash & Short-term Investments0.00
Prepaid Expense, Current AS0.00
Total Current Assets0.18
Intangible Assets0.16
Other Assets, Noncurrent0.00
Total Assets0.33
Liabilities
Accounts Payable1.20
Accrued Liabilities, Current AC0.84
Derivative Liability, Current DE0.37
Short-term Debt0.36
Other Liabilities, Current2.51
Deferred Compensation Share-based Arrangements, Liability, Current DE10.00
Total Current Liabilities5.27
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Total Liabilities5.27
Stockholders' Equity
Common Stock Value0.11
Additional Paid In Capital Common Stock18.63
Retained Earnings / Accumulated Deficit-23.73
Other Equity0.00
Common Stockholder's Equity-4.98
Preferred Stockholder's Equity0.04
Total Stockholder's Equity-4.94
Liabilities & Stockholder's Equity0.33
4 historic quarters locked

Sign in to unlock the full Bioxytran Inc balance sheet history.

About Bioxytran Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-038327

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.